
Overview
Status
Active
Registry date
2024-09-06
Share capital
5,000.00 PLN
Registered address
ul. Mokotowska 49A/2, 00-549 Warszawa, Poland
Website
Opening hours
- Monday–Friday
- 8:00–17:00
Electronic delivery address
AE:PL-81399-59355-HWRTC-16
Financials
Filing timeliness
The financial statement for 2025 was filed on time.
- 202521/05/2026
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 685.70kMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD -47.64kMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 702.83kMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 385.87kMedianUSD 608.93kAverageUSD 11.85m
Industry
Offer
- Dental implants
- Surgical kits
- Implantology instruments
- Dental scanners
- Implantology training
Website technology
- Analytics and marketing
- Google Tag Manager
- Meta Pixel
Authorized Representatives
Denys Hlovatskyi – President of the Management Board
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Denys Hlovatskyiage 40 | 91 | $1,229.07 | 91% |
Others | 9 | $121.56 | 9% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2024-09-27.
92 1020 1013 0000 0302 0535 8025
87 1020 1013 0000 0502 0535 8017
97 1020 1013 0000 0102 0535 8033
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Kleemed Pharmaceuticals Polandsp. z o.o. | $847,166.12 | kleemed.com.pl | ||
| Novisc Pharmasp. z o.o. | $806,018.56 | novisc.com | ||
| Capeypharmasp. z o.o. | $723,168.08 | capeypharma.com | ||
| Biotic Biomesp. z o.o. | $689,147.75 | bioticbiome.pl | ||
| Goodwill Pharma Polskasp. z o.o. | $664,724.30 | goodwillpharma.com | ||
| Pro Pedissp. z o.o. | $635,740.48 | propedis.pl | ||
| Dental Solutionssp. z o.o. | $611,683.37 | dentalsolutions.pl | ||
| IHT Polskasp. z o.o. | $566,313.48 | ihtpolska.com | ||
| Gursk Medicasp. z o.o. | $533,430.01 | gurskmedica.pl | ||
| Asmedi Internationalsp. z o.o. | $408,113.21 | asmediinternational.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-03-30 | Address change (Ul. Pańska 96/83, 00-837, Warszawa → Ul. Mokotowska 49a/2, 00-549, Warszawa) | |
| 2025-02-13 | Address change (Ul. Juliana Bartoszewicza 3/24, 00-337, Warszawa → Ul. Pańska 96/83, 00-837, Warszawa) | |
| 2025-02-13 | Name change (Amexmed → Biogentech Polska) | |
| 2024-09-06 | Entered in the register |
FAQ
The main business activity of Biogentech Polska focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on September 6, 2024.
The headquarters is located at: ul. Mokotowska 49A, 00-549 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from September 2, 2024 to December 31, 2025.
In 2025, the company generated total revenue of $685,704.
No, in 2025 the company was not profitable, reporting a net loss of $47,645.
The largest operating cost category falls under other operating costs. This category amounted to $401,434 in 2025, representing 57% of all operating expenses.
Last updated: 2026-05-21